Brooks Laboratories Limited

As of June 30, 2026, Brooks Laboratories Limited carries a market capitalization of 2.03B, placing it among publicly traded companies globally. Its enterprise value stands at 2.03B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Brooks Laboratories Limited has 29.46M shares outstanding.

As of June 30, 2026, Brooks Laboratories Limited trades at a trailing price-to-earnings ratio of 15.30.

As of June 30, 2026, Brooks Laboratories Limited trades at an EV/EBITDA multiple of 35.00 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.44 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 48.50 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.03B versus a market cap of 2.03B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 2.48M in revenue per employee across its workforce of 335.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Brooks Laboratories Limited's stock has declined approximately 49.49% over the past 52 weeks. The 50-day moving average sits at 62.54, while the 200-day moving average is 63.86.

Over the twelve months ended June 30, 2026, Brooks Laboratories Limited generated 831.87M in revenue and converted that into 132.12M in net income, yielding earnings per share of 4.50. EBITDA reached 57.96M, while operating income came in at 41.82M.

Over the twelve months ended June 30, 2026, Brooks Laboratories Limited posted a gross margin of 42.53, reflecting its pricing power and cost economics. The operating margin of 5.03 and net profit margin of 15.88 provide insight into operational efficiency.

Brooks Laboratories Limited's most recent stock split took place on July 28, 2023 with a 715:722 split ratio.